Related Experiment Video

Updated: Aug 26, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

29.1K

Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized,

Mehran Rahimlou1,2, Shima Nematollahi1, Durdana Husain1

  • 1Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Frontiers in Neuroscience
|October 7, 2022
PubMed
Abstract

Insights

Probiotic supplementation significantly reduced key inflammatory markers like CRP, TNF-α, and IFN-γ in multiple sclerosis (MS) patients. This suggests probiotics may offer benefits for managing systemic inflammation in MS.

Area of Science:

  • Immunology
  • Microbiology
  • Neurology

Background:

  • Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease affecting millions globally.
  • The gut microbiome is increasingly recognized for its role in chronic inflammatory conditions.

Purpose of the Study:

  • To evaluate the impact of probiotic supplementation on systemic inflammation markers in patients diagnosed with MS.

Main Methods:

  • A 12-week, double-blind, placebo-controlled clinical trial involving seventy MS patients.
  • Participants were randomized to receive either multi-strain probiotics or a placebo daily.
  • Systemic inflammation markers were measured at baseline and study completion.

Main Results:

  • Probiotic intake significantly decreased serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ).
  • Elevated levels of FOXP3 and transforming growth factor-beta (TGF-β) were observed in the probiotic group.
  • No significant baseline differences were noted between groups, except for disease duration.

Conclusions:

  • Probiotic supplementation demonstrates potential benefits in modulating systemic inflammation in individuals with multiple sclerosis.
  • These findings highlight the therapeutic potential of probiotics in managing inflammatory aspects of MS.
Keywords:
clinical trialgut microbiomeinflammationmultiple sclerosisprobiotic

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

19.7K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
397
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
173
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
250
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
352
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
190
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
215